Literature DB >> 2428813

Improved method for the isolation and preliminary characterization of human DAF (decay-accelerating factor).

Y Sugita, T Negoro, T Matsuda, T Sakamoto, M Tomita.   

Abstract

DAF (decay-accelerating factor) is one of the integral membrane proteins of erythrocytes, and is considered to play an important role in the regulation of complement activation. The purification of DAF has been impeded by the difficulty in removing glycophorin. We devised an effective method for removing glycophorin. Through the limited trypsinization of stromata prior to the extraction of DAF, glycophorin was readily digested so that the DAF could be purified free of glycophorin by DEAE-Sephacel and Bio-Gel A 0.5 m chromatographies. On SDS-PAGE, DAF from trypsinized stromata showed the same mobility as that from native stromata: its molecular weight was estimated to be about 70 kDa. Amino acid analysis of DAF showed high contents of serine and glutamic acid. The amino-terminal sequence of DAF prepared by the present method, determined for the 29 residues, did not show significant homology with that of glycophorin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428813     DOI: 10.1093/oxfordjournals.jbchem.a121686

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  5 in total

1.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC).

Authors:  T Inaba; M Mizuno; S Ohya; M Kawada; T Uesu; J Nasu; K Takeuchi; M Nakagawa; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

3.  Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.

Authors:  M F Horta; F J Ramalho-Pinto; M Fatima
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

Review 4.  Current perspectives on camptothecins in cancer treatment.

Authors:  J Dancey; E A Eisenhauer
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.

Authors:  M J Telen; S E Hall; A M Green; J J Moulds; W F Rosse
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.